Sanofi Appoints Dominique Carouge Executive Vice President Head of Business Transformation and Member of the Executive Commit...
19 Janvier 2018 - 6:00PM
Press
Release
Source: Sanofi (EURONEXT: SAN) (NYSE: SNY)
Sanofi Appoints Dominique Carouge Executive Vice President Head of
Business Transformation and Member of the Executive
Committee
Paris, France - January 19, 2018 -
Sanofi has appointed Dominique Carouge as Executive Vice
President Head of Business Transformation, effective February 15,
2018. In this role, Mr. Carouge will be in charge of accelerating
the transformation of the Company and will be a member of the
Executive Committee. He has served as Deputy CFO and Head of
Finance Operations and Group Controlling since January 1st,
2016.
Mr. Carouge previously served as
Vice-President, Administration & Management for Global R&D
since 2011. Prior to that, Mr. Carouge held the role of VP, Chief
Strategy and Finance Officer for Sanofi Pasteur since 2009.
Mr. Carouge started his career in
1985 as an external auditor at Ernst & Young (EY) both in
France (Paris) and in the US (Philadelphia). He joined Sanofi in
1991. Since then and for the past 27 years, he held various finance
positions of increasing responsibility and leadership across
Australia, New Zealand, Germany and France.
A citizen of France, Mr. Carouge
graduated from "Ecole Supérieure de Commerce de Reims". He also
holds a CPA degree in France, as well as a Corporate Governance and
Board management certificate from Sciences Po (Certificat
d'Administrateur de Sociétés).
About Sanofi
Sanofi is dedicated to supporting people through their health
challenges. We are a global biopharmaceutical company focused on
human health. We prevent illness with vaccines, provide innovative
treatments to fight pain and ease suffering. We stand by the few
who suffer from rare diseases and the millions with long-term
chronic conditions.
With more than 100,000 people in 100 countries, Sanofi is
transforming scientific innovation into healthcare solutions around
the globe.
Sanofi, Empowering Life
|
|
|
Media Relations
Laurence Bollack
Tel. : +33 (0)1 53 77 46 46
mr@sanofi.com |
Investor Relations George Grofik
Tel. : +33 (0)1 53 77 45 45
ir@sanofi.com |
Sanofi Forward-Looking Statements This press release
contains forward-looking statements as defined in the Private
Securities Litigation Reform Act of 1995, as amended.
Forward-looking statements are statements that are not historical
facts. These statements include projections and estimates regarding
the marketing and other potential of the product, or regarding
potential future revenues from the product. Forward-looking
statements are generally identified by the words "expects",
"anticipates", "believes", "intends", "estimates", "plans" and
similar expressions. Although Sanofi's management believes that the
expectations reflected in such forward-looking statements are
reasonable, investors are cautioned that forward-looking
information and statements are subject to various risks and
uncertainties, many of which are difficult to predict and generally
beyond the control of Sanofi, that could cause actual results and
developments to differ materially from those expressed in, or
implied or projected by, the forward-looking information and
statements. These risks and uncertainties include among other
things, unexpected regulatory actions or delays, or government
regulation generally, that could affect the availability or
commercial potential of the product, the absence of guarantee that
the product will be commercially successful, the uncertainties
inherent in research and development, including future clinical
data and analysis of existing clinical data relating to the
product, including post marketing, unexpected safety, quality or
manufacturing issues, competition in general, risks associated with
intellectual property and any related future litigation and the
ultimate outcome of such litigation, and volatile economic
conditions, as well as those risks discussed or identified in the
public filings with the SEC and the AMF made by Sanofi, including
those listed under "Risk Factors" and "Cautionary Statement
Regarding Forward-Looking Statements" in Sanofi's annual report on
Form 20-F for the year ended December 31, 2016. Other than as
required by applicable law, Sanofi does not undertake any
obligation to update or revise any forward-looking information or
statements.
|
Press release (PDF)
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Sanofi via Globenewswire
Sanofi (EU:SAN)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Sanofi (EU:SAN)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024